# US 2009/0022793 A1 · Mesalamine suppository

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0022793 A1
- Document ID: US20090022793A1
- Status: Published application
- Kind: A1
- Application number: 12/245,648
- Filed: 2008-10-03
- Published: 2009-01-22
- Earliest claimed: 2007-06-08
- Assignees: Axcan Pharma Inc.
- Inventors: Carl Gauthier; Yves Dumoulin; David Powell
- Web page: https://patentgrep.com/patent/US20090022793A1

## CPC

- A61K 9/02: Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00)
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.

## Claims

### Claim 1

A mesalamine rectal suppository comprising from about 850 to about 1150 mg of mesalamine and one or more pharmaceutically acceptable excipients, wherein the mesalamine has a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>), the drug load of the suppository ranges from 35% to 50%, and the suppository releases at least about 75% by weight of the mesalamine within 2 hours of dissolution as measured with USP Apparatus #2 at 40° C., a paddle rotation speed of 125 rpm, and 3 sinker turns in 0.2 M phosphate buffer at a pH of 7.5.

### Claim 2 (depends on 1)

The mesalamine suppository of claim 1, wherein the amount of mesalamine ranges from about 950 to about 1050 mg.

### Claim 3 (depends on 1)

The mesalamine suppository of claim 1, wherein at least one pharmaceutically acceptable excipient has an ascending melting point ranging from 32 to 33.5° C.

### Claim 4 (depends on 3)

The mesalamine suppository of claim 3, wherein the pharmaceutically acceptable excipient having an ascending melting point ranging from 32 to 33.5° C. is an oily or fatty base.

### Claim 5 (depends on 1)

The mesalamine suppository of claim 1, wherein at least one pharmaceutically acceptable excipient is an oily or fatty base having an ascending melting point from 33 to 35.5° C.

### Claim 6 (depends on 4)

The mesalamine suppository of claim 4, the oily or fatty base is hard fat.

### Claim 7 (depends on 5)

The mesalamine suppository of claim 5, the oily or fatty base is hard fat.

### Claim 8 (depends on 1)

The mesalamine suppository of claim 1, wherein the drug load ranges from about 39 to about 45%.

### Claim 9 (depends on 8)

The mesalamine suppository of claim 8, wherein the drug load ranges from about 41 to about 43%.

### Claim 10 (depends on 1)

The mesalamine suppository of claim 1, wherein the suppository releases at least about 80% by weight of the mesalamine within 2 hours of dissolution as measured with USP Apparatus #2 at 40° C., a paddle rotation speed of 125 rpm, and 3 sinker turns in 0.2 M phosphate buffer at a pH of 7.5.

### Claim 11 (depends on 1)

The mesalamine suppository of claim 1, wherein the suppository releases at least about 80% by weight of the mesalamine within 1 hour of dissolution as measured with USP Apparatus #2 at 40° C., a paddle rotation speed of 125 rpm, and 3 sinker turns in 0.2 M phosphate buffer at a pH of 7.5.

### Claim 12 (depends on 1)

The mesalamine suppository of claim 1, wherein the suppository releases at least 90% by weight of the mesalamine within 30 minutes of dissolution as measured with USP Apparatus #2 at 40° C., a paddle rotation speed of 125 rpm, and 3 sinker turns in 0.2 M phosphate buffer at a pH of 7.5.

### Claim 13 (depends on 1)

A method of treating active ulcerative proctitis in a patient in need thereof comprising administering the mesalamine rectal suppository of claim 1 to the patient.

### Claim 14 (depends on 13)

The method of claim 13, wherein the mesalamine rectal suppository is administered once a day.

### Claim 15 (depends on 14)

The method of claim 14, wherein the mesalamine rectal suppository is administered once a day at bedtime.
